Bill Begien - Conduit Pharmaceuticals Senior Relations
| CDT Stock | 0.89 0.08 8.25% |
Executive
Bill Begien is Senior Relations of Conduit Pharmaceuticals
| Address | 4995 Murphy Canyon Road, San Diego, CA, United States, 92123 |
| Phone | 760 471 8536 |
| Web | https://www.conduitpharma.com |
Conduit Pharmaceuticals Management Efficiency
The company has Return on Asset of (1.088) % which means that on every $100 spent on assets, it lost $1.088. This is way below average. Conduit Pharmaceuticals' management efficiency ratios could be used to measure how well Conduit Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Conduit Pharmaceuticals' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.06 in 2025, whereas Return On Capital Employed is likely to drop 0.1 in 2025. Total Current Liabilities is likely to gain to about 653.8 M in 2025. Liabilities And Stockholders Equity is likely to gain to about 3.4 B in 2025Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bao Bauduin | Starbucks | 49 | |
| Tiffany CPA | Starbucks | N/A | |
| Emmy Kan | Starbucks | N/A | |
| Tiffany Willis | Starbucks | N/A | |
| Christopher Pinsak | BJs Restaurants | 60 | |
| Brian Krakower | BJs Restaurants | 54 | |
| Michelle Burns | Starbucks | N/A | |
| Megan Tobin | Dave Busters Entertainment | 39 | |
| Jacob Guild | BJs Restaurants | N/A | |
| Putnam Shin | BJs Restaurants | 46 | |
| Heidi Rogers | BJs Restaurants | N/A | |
| Brady Brewer | Starbucks | 52 | |
| Megan Estrada | Dave Busters Entertainment | N/A | |
| Maria Bell | U Haul Holding | 54 | |
| Aranthan II | Starbucks | 47 | |
| Steven Klohn | Dave Busters Entertainment | 51 | |
| MD MBA | U Haul Holding | 47 | |
| Cory Hatton | Dave Busters Entertainment | N/A | |
| Dina BarmasseGray | The Cheesecake Factory | N/A | |
| Etienne Marcus | The Cheesecake Factory | N/A | |
| Amy Krallman | BJs Restaurants | 57 | |
Management Performance
| Return On Asset | -1.09 |
Conduit Pharmaceuticals Leadership Team
Elected by the shareholders, the Conduit Pharmaceuticals' board of directors comprises two types of representatives: Conduit Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Conduit. The board's role is to monitor Conduit Pharmaceuticals' management team and ensure that shareholders' interests are well served. Conduit Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Conduit Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tapolczay, CEO Director | ||
| James Bligh, Interim Director | ||
| Adam Sragovicz, Chief Officer | ||
| Joanne Holland, Chief Officer | ||
| Bill Begien, Senior Relations |
Conduit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Conduit Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -1.09 | ||||
| Current Valuation | 9.39 M | ||||
| Shares Outstanding | 6.2 M | ||||
| Shares Owned By Insiders | 13.92 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 562.28 K | ||||
| Revenue | 2.46 B | ||||
| EBITDA | 266.46 M | ||||
| Net Income | 198.41 M | ||||
| Total Debt | 1.23 B |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.